David Osser

David Osser, Associate Professor of Psychiatry at Harvard Medical School and psychopharmacology expert, gives concise clinical guidance on lithium. He reviews essential baseline labs, formulation differences, and why once-daily immediate-release dosing may protect kidneys. He covers starting doses, monitoring timing, interacting drugs, target levels for acute and maintenance care, tapering risks, and special population considerations.

Dr. David Osser, an Associate Professor of Psychiatry at Harvard Medical School and expert in bipolar treatment, argues for lithium as the first-line therapy for classic mania. He presents compelling evidence of lithium's neuroprotective benefits and long-term efficacy, emphasizing its role in reducing suicide risk and preventing episodes. Comparisons of second-generation antipsychotics reveal their limited advantages over lithium. Osser’s insights challenge the reliance on antipsychotics, advocating for lithium's unique advantages in managing bipolar disorder.

David Osser, Associate Professor of Psychiatry at Harvard Medical School and psychopharmacology expert, breaks down lithium's renal risks with clear evidence. He discusses actual risk numbers and who is higher risk. He covers monitoring frequency, dosing strategies to prevent toxicity, key drug interactions, and practical approaches for managing polyuria and edema.

David Osser, an associate professor of psychiatry at Harvard Medical School and psychopharmacology expert, shares his insights on treating acute mania. He discusses effective strategies for augmenting lithium, highlighting quetiapine as the preferred add-on due to its mood-stabilizing effects. Osser critiques the overuse of valproate and explains the minimal benefits from combining it with lithium based on the BALANCE study. He also warns of metabolic risks associated with drug combinations, providing vital considerations for patient care.

Dr. David Osser, Associate Professor of Psychiatry at Harvard Medical School, shares his expertise on managing mixed manic episodes. He discusses the critical timing for adding lithium or valproate to antipsychotics, emphasizing patience and evidence-based strategies. Osser cautions against rushing into combination therapies due to managed care pressures and advocates for temporary use of benzodiazepines to stabilize patients. He weighs the pros and cons of lithium versus valproate and considers carbamazepine as a viable third-line option.